1. Home
  2. BLTE vs KVYO Comparison

BLTE vs KVYO Comparison

Compare BLTE & KVYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$161.06

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Logo Klaviyo Inc. Series A

KVYO

Klaviyo Inc. Series A

N/A

Current Price

$18.33

Market Cap

5.3B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BLTE
KVYO
Founded
2018
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.3B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
BLTE
KVYO
Price
$161.06
$18.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
21
Target Price
$198.00
$34.48
AVG Volume (30 Days)
153.2K
6.0M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
35.29
EPS
N/A
N/A
Revenue
N/A
$1,234,019,000.00
Revenue This Year
N/A
$24.47
Revenue Next Year
$492.11
$19.66
P/E Ratio
N/A
$657.67
Revenue Growth
N/A
31.63
52 Week Low
$62.18
$12.53
52 Week High
$200.00
$36.23

Technical Indicators

Market Signals
Indicator
BLTE
KVYO
Relative Strength Index (RSI) 51.24 52.40
Support Level $158.32 $15.67
Resistance Level $172.02 $19.32
Average True Range (ATR) 6.82 1.22
MACD -0.74 -0.07
Stochastic Oscillator 27.85 62.82

Price Performance

Historical Comparison
BLTE
KVYO

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

Share on Social Networks: